Q4 2024 Evogene Ltd Earnings Call Transcript
Key Points
- Evogene Ltd (EVGN) reported a significant increase in total revenues for 2024, reaching approximately $8.5 million compared to $5.6 million in 2023.
- The company successfully addressed a bottleneck in seed production, with Castera delivering 250 tons of Castor seeds in February 2025, surpassing the total delivery for the entire year of 2024.
- Evogene Ltd (EVGN) has established a collaboration with Google Cloud to develop a generative AI foundation model for novel small molecule design, enhancing its capabilities in drug discovery.
- The company has implemented an expense reduction plan, resulting in a 30% reduction in headcount, which is expected to reflect positively on financials starting Q1 2025.
- Evogene Ltd (EVGN) achieved a significant milestone in its operational expansion by completing the first shipment of over 100 tons of Castor seeds grown and processed in Kenya.
- The change in the delivery schedule of Castera seeds from 2024 to 2025 led to lower-than-expected revenues in Q4 2024.
- Total R&D expenses for 2024 were approximately $16.6 million, although decreased from 2023, they still represent a significant portion of the company's expenditures.
- General and administrative expenses increased to approximately $7.4 million in 2024, partly due to one-time expenses related to fundraising and a provision for doubtful debt.
- The company reported an operating loss of approximately $22.2 million for 2024, despite increased revenues and decreased R&D expenses.
- Evogene Ltd (EVGN) did not provide specific cash burn guidance for 2025, creating uncertainty about future financial stability.
Welcome to Evogene's. fourth quarter results conference call. (Operator Instructions) As a reminder, this conference is being recorded March 6, 2025.
Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogene's management will constitute forward-looking statements that relate to future events. This presentation contains forward-looking statements relating to future events, and Evogene LTD, the company.
From time to time make other statements regarding our outlook or expectations for future financial or operating results and or other matters regarding or affecting us that are considered forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1,995 and other securities laws as amended statements that are not statements of historical fact.
May be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should planned, estimated, intend, and potential, or words of similar meaning we are using.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
